- Title
- Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial
- Creator
- Wark, Peter Alexander Blanch; Hensley, Michael John; Saltos, Nicholas; Boyle, Michael James; Toneguzzi, Ruth Christine; Simpson, Jodie Louise; McElduff, Patrick; Gibson, Peter Gerard
- Relation
- Journal of Allergy and Clinical Immunology Vol. 111, Issue 5, p. 952-957
- Publisher Link
- http://dx.doi.org/10.1067/mai.2003.1388
- Publisher
- Mosby, Inc
- Resource Type
- journal article
- Date
- 2003
- Description
- Background: Allergic bronchopulmonary aspergillosis (ABPA) complicates chronic asthma and results from hypersensitivity to the fungus Aspergillus fumigatus, causing an intense systemic immune response and progressive lung damage. Objective: We sought to determine whether treatment with the antifungal agent itraconazole reduced eosinophilic airway inflammation in subjects with ABPA. Methods: A randomized, double-blind, placebo-controlled trial was performed in stable subjects with ABPA (n=29). Subjects received 400 mg of itraconazole per day (n=15) or placebo (n=14) for 16 weeks. All subjects were reviewed monthly with history, spirometry, and sputum induction to measure airway inflammation, serum total IgE and IgG levels to A fumigatus, and blood eosinophil counts. Results: By using regression analysis in a random-effects model, subjects receiving itraconazole had a decrease in sputum eosinophils of 35% per week, with no decrease seen in the placebo arm (P<.01). Sputum eosinophil cationic protein levels decreased with itraconazole treatment by 42% per week compared with 23% in the placebo group (P<.01). Itraconazole reduced systemic immune activation, leading to a decrease in serum IgE levels (310 IU/mL) compared with levels seen in the placebo group (increase of 18 IU/mL, P<.01) and a decrease in IgG levels to A fumigatus (15.4 IU/mL) compared with levels seen in the placebo group (increase of 3.7 IU/mL, P =.03). There were fewer exacerbations requiring oral corticosteroids in those treated with itraconazole compared with in the placebo group (P=.03). Conclusion: Itraconazole treatment of subjects with stable ABPA reduces eosinophilic airway inflammation, systemic immune activation, and exacerbations. These results imply that itraconazole is a potential adjunctive treatment for ABPA.
- Subject
- itraconazole; allergic bronchopulmonary aspergillosis; airway inflammation; induced sputum; asthma
- Identifier
- uon:1763
- Identifier
- http://hdl.handle.net/1959.13/27529
- Identifier
- ISSN:0091-6749
- Reviewed
- Hits: 6972
- Visitors: 7413
- Downloads: 0
| Thumbnail | File | Description | Size | Format |
|---|